Anticoagulant Therapy for Cancer-Associated Thrombosis : A Cost-Effectiveness Analysis.

ABSTRACT:

Background

Direct oral anticoagulants (DOACs) offer an alternative to low-molecular-weight heparin (LMWH) and warfarin for treating cancer-associated thrombosis (CAT).

Objective

To determine the cost and effectiveness of DOACs versus LMWH.

Design

Cohort-state transition decision analytic model.

Data sources

Network meta-analysis comparing DOACs versus LMWH.

Target population

Adult patients with cancer at the time they develop thrombosis.

Time horizon

Lifetime.

Perspective

Health care sector.

Intervention

Strategies of 1) enoxaparin, 2) apixaban, 3) edoxaban, and 4) rivaroxaban for treatment of CAT.

Outcome measures

Incremental cost-effectiveness ratio (ICER) in 2022 U.S. dollars per quality-adjusted life-year (QALY) gained.

SUBMITTER: Gulati S 

PROVIDER: S-EPMC10279520 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature